Our main partners and collaborators are the Josep Carreras Leukaemia Research Institute (IJC), the Josep Carreras Leukaemia Foundation and AOP Health. The IJC is established in three different campuses (Campus Clínic-UB, Campus ICO-Germans Trias i Pujol and Campus Sant Pau) that allow and easy access to science, academia, specialized oncologists and patients.

In July 2022, Leukos Biotech established a partnership with AOP Health to further develop the company’s lead candidate, LB208. This new partnership seeks to further expand research and development of the molecule within Hematology/Oncology but also to other indications. The AOP Health Group (AOP Health) is a European pioneer in integrated therapies for rare diseases and critical care. The company focuses on research, development and global sales of innovative treatment solutions and specializes in therapies for rare diseases and intensive care.